Ampersand Capital Partners Recapitalizes American Laboratory Products Company (ALPCO)
September 21, 2020
Ampersand Capital Partners completed a majority recapitalization of American Laboratory Products Company (ALPCO) to provide growth capital for expanding ALPCO's diagnostics test kit offering, geographic reach, and R&D/production capabilities. Founders Richard and Jan Conley will remain shareholders, Sean Conley will continue as CEO, and Larry McCarthy, PhD was named Board Chairman.
- Buyers
- Ampersand Capital Partners
- Targets
- American Laboratory Products Company (ALPCO)
- Sellers
- Richard Conley, Jan Conley
- Industry
- Medical Devices
- Location
- New Hampshire, United States
- Transaction Type
- Recapitalization
Explore More
Related Acquisitions
-
Ampersand Capital Partners Acquires Specac Ltd.
March 13, 2024
Manufacturing
Ampersand Capital Partners, a Boston-based private equity firm focused on healthcare and life sciences, has acquired Specac Ltd., a UK-based designer and manufacturer of FTIR spectroscopy accessories and sample preparation solutions. The acquisition will support Specac's growth trajectory and leverage Ampersand's experience in life-sciences-oriented lab products and OEM channels.
-
American Laboratory Products Company (ALPCO) Merges with GeneProof
April 21, 2022
Medical Devices
American Laboratory Products Company (ALPCO) announced a merger with GeneProof a.s., combining ALPCO's immunodiagnostics capabilities with GeneProof's molecular diagnostics products and instruments. The combined company will be majority owned by Ampersand Capital Partners (which previously recapitalized ALPCO), with GeneProof's founders remaining as significant shareholders to support expanded global commercialization, including entry into the U.S. market.
-
Ampersand Capital Partners Invests in Alliance Pharma
November 18, 2021
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in Alliance Pharma, a Malvern, Pennsylvania–based bioanalytical CRO. The funding will support Alliance’s expansion of global reach, scientific capabilities, and operational capacity while founder Frank Li remains a significant shareholder.
-
Ampersand Capital Partners Majority Recapitalizes Leinco Technologies
November 10, 2021
Biotechnology
Ampersand Capital Partners has completed a majority recapitalization of Leinco Technologies, a specialty manufacturer of life-science reagents and custom development services based near St. Louis, Missouri. The growth equity investment will fund expanded manufacturing capacity, broaden scientific capabilities and product offerings, and support Leinco's commercial and geographic expansion while leadership including founder Pat Leinert Sr. remain involved.
-
Ampersand Capital Partners Majority Recapitalizes New England Peptide
October 7, 2019
Biotechnology
Ampersand Capital Partners completed a majority recapitalization of New England Peptide to support the company's worldwide growth initiatives and expand its peptide synthesis capabilities. As part of the transaction, Dr. José de Chastonay was appointed Executive Chairman; founders Sam and Jennifer Massoni remain noted in the announcement.
-
Ampersand Capital Partners Majority Recapitalizes N2 Biomedical
June 18, 2019
Medical Devices
Ampersand Capital Partners completed a majority recapitalization of N2 Biomedical, a Bedford, Massachusetts-based provider of coating and surface treatment solutions for the medical device industry. The transaction positions N2 to accelerate growth and broaden its service offering; Ampersand also supported the appointment of Randall Sword as President and CEO while co-founders remain shareholders.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.